Terms: = Liver cancer AND FAT1, CDHF7, 2195, ME5, hFat1, CDHR8 AND Prognosis
5 results:
1. Identification of tumor mutation burden-associated molecular and clinical features in cancer by analyzing multi-omics data.
Li M; Gao X; Wang X
Front Immunol; 2023; 14():1090838. PubMed ID: 36911742
[TBL] [Abstract] [Full Text] [Related]
2. Preoperative serum ctDNA predicts early hepatocellular carcinoma recurrence and response to systemic therapies.
Fu Y; Yang Z; Hu Z; Yang Z; Pan Y; Chen J; Wang J; Hu D; Zhou Z; Xu L; Chen M; Zhang Y
Hepatol Int; 2022 Aug; 16(4):868-878. PubMed ID: 35674872
[TBL] [Abstract] [Full Text] [Related]
3. Early Recurrence in Resected Gallbladder Carcinoma: Clinical Impact and Its Preoperative Predictive Score.
Shimizu Y; Ashida R; Sugiura T; Okamura Y; Ohgi K; Yamada M; Otsuka S; Aramaki T; Notsu A; Uesaka K
Ann Surg Oncol; 2022 Sep; 29(9):5447-5457. PubMed ID: 35666409
[TBL] [Abstract] [Full Text] [Related]
4. A novel immune classification reveals distinct immune escape mechanism and genomic alterations: implications for immunotherapy in hepatocellular carcinoma.
Liu Z; Zhang Y; Shi C; Zhou X; Xu K; Jiao D; Sun Z; Han X
J Transl Med; 2021 Jan; 19(1):5. PubMed ID: 33407585
[TBL] [Abstract] [Full Text] [Related]
5. Whole exome sequencing reveals recurrent mutations in BRCA2 and FAT genes in acinar cell carcinomas of the pancreas.
Furukawa T; Sakamoto H; Takeuchi S; Ameri M; Kuboki Y; Yamamoto T; Hatori T; Yamamoto M; Sugiyama M; Ohike N; Yamaguchi H; Shimizu M; Shibata N; Shimizu K; Shiratori K
Sci Rep; 2015 Mar; 5():8829. PubMed ID: 25743105
[TBL] [Abstract] [Full Text] [Related]
